Search the site for any medical term or simply browse by disease topic. Access all the information you need in one place, when you need it, how you want it and for free!
Launch of accredited Type 1 Childhood Diabetes CME
A new EACCME-accredited CME activity Individual Patient Management in Type 1 Childhood Diabetes has launched on epgonline.org. Intended for medical professionals involved in the management of young patients with type 1 diabetes, this module consists of six sessions, each covering a different aspect of managing psychosocial issues in type 1 childhood diabetes.
Explore at your own pace and test your knowledge using the interactive learning exercises. The activity is totally free, and on completion you will be awarded 1 European CME credit (ECMEC).
Anti-Infectives Knowledge Network (AIKN) CDI Updates
Recently updated with new reports and policy updates as well as key perspectives on Clostridium difficile infection (CDI), the Anti-Infectives Knowledge Network shares expertise and experience in the area of anti-infectives.
This educational resource is an initiative by Astellas Pharma EMEA. Please remember to return often to read the news, clinical insights, and essential information from the latest anti-infective congresses.
January 2015 FDX/15/0003/EU
This free CME activity covers the best practice management of nocturnal enuresis through three case study-led modules, including a more severe and complex patient scenario. It is intended for Urologists, Paediatricians, Primary Care Providers and General Practitioners looking to improve their understanding and management of bedwetting.
Accredited Obesity CME
The EACCME accredited European Obesity Initiative eCME module – Understanding Obesity, is freely accessible to healthcare professionals. Upon successful completion, participants will be awarded 2 European CME credits (ECMECs) and have a broad understanding of the epidemiology, contributory factors and management options for patients with obesity.
Type 2 Diabetes accredited CME
‘Role of Newer Therapies for Type 2 Diabetes in Combination with Insulin’ is EACCME accredited and awarded 1 European CME credit (ECMEC). There are 3 modules:
- A Review of Newer Therapies for Type 2 Diabetes in Combination with Insulin; John Wilding (Chair)
- Identifying and Managing the Psychosocial Aspects of Type 2 Diabetes Mellitus; Richard Holt (Faculty)
- Potential Role of Newer Therapies for Type 2 Diabetes in Combination with Insulin: Interactive Case Discussion; Bernard Charbonnel (Faculty)
Sorin S.p.A. a global medical device company and a leader in the treatment of cardiovascular diseases, and Cyberonics Inc. a medical device company with core expertise in neuromodulation, announced their merger plan to create a new global leader in ...
FDA approves Toujeo (insulin glargine [rDNA origin]) for treatment of Type 1 and Type 2 Diabetes-Sanofi27-Feb-2015
Sanofi announced that the FDA approved Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes. Toujeo is expected to be ...
FDA panel recommends approval for KXL System + combined riboflavin for corneal ectasia and ketatoconus- Avedro27-Feb-2015
The FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee and Ophthalmic Devices Panel recommended approval of combined riboflavin ophthalmic solutions and ultraviolet light irradiation for corneal collagen cross-linking from Avedro.Photrexa ...
Amgen has announced results from the head-to-head Phase III study comparing AMG 416 with cinacalcet for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) receiving hemodialysis. The study met the ...
Teva Pharmaceutical Industries Ltd., announced that the FDA has accepted for review the New Drug Application (NDA) for the company’s hydrocodone bitartrate extended-release (ER) tablets formulated with Teva’s proprietary abuse deterrence technology ...
The European Commission has approved the use of Xadago (safinamide), from Newron Pharmaceuticals, for the treatment of idiopathic Parkinson’s disease. The drug has been approved for mid-to late-stage fluctuating patients as add-on therapy to a stable ...
Boston Scientific Corp is close to buying Endo International PLC's AMS medical device unit, a deal that could value the business at around $2 billion, The companies are aiming to finalize an agreement within a matter of weeks, the people said this ...